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Gene expression changes evoked in a venous
segment exposed to arterial flow
Deborah Abeles, MD, Stephanie Kwei, MD, George Stavrakis, MS, Yuzhi Zhang, MS,
Eric T. Wang, AB, and Guillermo García-Cardeña, PhD, Boston, Mass
Objective: This study was conducted to characterize the coordinated molecular changes evoked in the structure and
composition of the wall of a venous segment when exposed to fistula flow.
Methods: An arteriovenous shunt was created in adult C57BL/6J mice. Remodeled veins and contralateral control jugular
veins were isolated 7 days after surgery. Total RNA was isolated, linearly amplified, and the transcriptional profiles of this
early adaptive response were obtained by microarray analysis. Histologic and immunohistochemical analyses were
performed on remodeled veins and control veins isolated on days 1, 3, 5, and 7 after surgery to further examine distinct
spatial and temporal aspects of this early process.
Results: There were 131 significantly upregulated and 165 downregulated genes in the remodeled vein compared with the
control jugular vein. Genes involved in extracellular matrix reorganization were highly upregulated. Movat’s penta-
chrome staining revealed ground substance on day 3 that was not observed on day 5. The appearance of elastin fibers was
first observed on day 7. Morphometric analysis demonstrated maximum wall thickness on day 3. Immunohistochemical
analysis revealed the presence of tenascin-C, thrombospondin, lysyl oxidase, and osteopontin in different cell types at
different time points throughout the first week after surgery.
Conclusion: Major changes in the organization of the extracellular matrix occur during the early response of venous
remodeling. Elastin, tenascin-C, thrombospondin, lysyl oxidase, and osteopontin are expressed within the wall of the
remodeling vein resulting in the de novo formation of an extracellular matrix scaffold that may be part of a critical adaptation
program being evoked to allow the vessel to cope with its new biomechanical environment. (J Vasc Surg 2006;44:863-70.)
Clinical Relevance: The Kidney Dialysis Outcomes Quality Initiative has proposed the construction of arteriovenous
fistulas as the primary vascular access for hemodialysis. As the vein is exposed to arterial flow, the vein wall dilates and a
vascular remodeling process is triggered. With continued exposure, intimal hyperplasia occurs at the anastomosis that in
many cases leads to failure. However, the molecular mechanisms by which the outflow vein remodels into a mature fistula
remain incompletely understood. By investigating venous remodeling in a fistula model, candidate genes important for
the remodeling process are discovered and their functional significance examined. Thus, the identification of relevant
genes involved in this process should provide insight into arteriovenous fistula maturation and may suggest novel
approaches for achieving higher patency rates.Arteriovenous fistulas (AVF) are the best vascular ac-
cess option for patients with end-stage renal disease on
hemodialysis.1 The ability of the venous outflow tract to
mature depends upon on the state and size of the vessels
and their ability to adapt to a change in hemodynamic
environment.2,3 During this adaptive period, the vein wall
senses the change in its biomechanical environment, and
the process of structural and functional changes in the
vascular wall, known as vascular remodeling, is initiated.4
Vascular smooth muscle cells (VSMC) migrate and prolif-
erate in the intima; and the vessel wall changes in response
to the new arterial environment and its associated shear
stress, oxygen tension, metabolite concentrations, and pH.5
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The extracellularmatrix (ECM)of amature vessel consists
of collagen, elastin, and ground substance composed of pro-
teoglycans, glycoproteins, and glycosaminoglycans. Proteo-
glycans bind water to form a gel-like substance.6 Although
vein walls have a thin layer of VSMCs and minimal elastin,
arterial walls are composed of alternating lamellae of VSMCs
and elastin, providing a crucial support structure that allows
it to sustain the hemodynamic pressures present in arterial
conduits.6,7 During venous remodeling, the vein wall as-
sembles a reinforced scaffolding capable of withstanding
the increased hemodynamic force of arterial flow.
Our laboratory previously developed and began to
characterize a mouse model of an AVF to investigate the
early stages of venous remodeling.8 In our model, this
corresponds with the first 7 days after surgery. Here, we
used transcriptional profiling approaches to define the ini-
tial molecular changes that occur in the vessel wall during
this adaptive period as it responds to a change in its biome-
chanical environment. We hypothesize that coordinated
molecular changes in the structure and composition of the
vessel wall are evoked as a vein is exposed to arterial flow.
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Surgical procedure. In this study, we used a mouse
model of an AVF with 8- to 10-week-old C57BL/6J male
mice that was recently developed in our laboratory8 in
which we observed strong remodeling using this strain and
age. We did not observe differences in remodeling between
genders. The mice were anesthetized by an intraperitoneal
injection of tribromoethanol, 125 to 240 mg/kg (Avertin,
Fisher Scientific, Pittsburgh, Penn). A vertical incision was
made over the right neck. The external jugular vein was
identified, and all branches were ligated and divided using
10-0 nylon (US Surgical, Norwalk, Conn). An arterio-
venous shunt was created between the jugular vein and the
common carotid artery by using a 2-mm microvascular
catheter (Fine Science Tools, Foster City, Calif) and se-
cured with 8-0 silk ties (US Surgical). Clamps were re-
moved and pulsatile flow was observed in the jugular vein.
Sham surgery was performed in which all branches of the
external jugular vein were ligated and divided using 10-0
nylon (US Surgical), the carotid artery was dissected free
from its surrounding tissue, and a 2-mm microvascular
catheter was placed next to both the jugular vein and the
carotid artery. In all cases, the incision was closed using 5-0
Vicryl suture (US Surgical). Operative time averaged 45 to
60 minutes.
All animal procedures and care were performed with
approval from the Institutional Animal Care and Use Com-
mittee and complied with the Guide of the Care and Use
of Laboratory Animals.9
Tissue isolation. External jugular vein segments ex-
posed to arterial flow were isolated on days 1, 3, 5, and 7
after surgery. The incision was reopened and the remodeled
vein was exposed and dissected free from the surrounding
tissue. Patency was confirmed by visualizing pulsatile arte-
rial flow in the vein segment. The contralateral jugular vein
was isolated as a control at all time points. The animal was
euthanized under anesthesia by cardiac puncture and inci-
sion of the left renal vein. Perfusion fixation at 110 mmHg
was performed using phosphate buffered saline (PBS), fol-
lowed by 2% paraformaldehyde via the left ventricle. A
4-mm segment of remodeled vein was isolated distal to the
microvascular catheter. The vessels were oriented and snap
frozen in optimal cutting temperature compound for cryo-
sectioning and histologic, and immunohistochemical stain-
ing. A 4-mm segment of sham operated jugular vein and
carotid artery was also isolated as a control and then snap
frozen after perfusion with PBS and 2% paraformaldehyde.
RNA extraction. A 4-mm segment of postoperative
day 7 remodeled vein and contralateral control jugular vein
were perfused with PBS, isolated, and frozen. To obtain
sufficient RNA for microarray analysis, the remodeled vein
from five mice were pooled in each experiment (n  3).
The tissue was pulverized and total RNA was extracted
using an RNeasy micro kit (Qiagen, Valencia, Calif). RLT
Buffer containing -mercaptoethanol (Qiagen) was added
to dissolve the tissue. This mixture was then applied to an
RNeasy micro column (Qiagen). The column was washedwith RW1, incubated with DNAse, and then serially
washed with RW1 and RPE. The RNA was eluted with
RNAse-free water.
Linear amplification of complimentary RNA. RNA
(500 ng) was used for linear amplification of complimen-
tary RNA (cRNA) based on the Low RNA Input Fluores-
cent Linear Amplification Kit (Agilent Technologies, Palo
Alto, Calif). cDNA was synthesized from the total RNA
using the T7 promoter primer, 5x first strand buffer, 0.1M
dithiothreitol (DTT), 10mMdeoxyribonucleotide triphos-
phate, Mouse Moloney Leukemia Virus reverse transcrip-
tase, and RNAseOUT. The reaction was incubated at 40°C
for 2 hours. Fluorescent complementary RNA (cRNA) was
synthesized from the cDNA by using an in vitro tran-
scription master mix consisting of nuclease free water,
transcription buffer, DTT, nucleotide triphosphate mix,
labeled cytidine 5’-triphosphate, 50% polyethylene glycol,
RNAseOUT, inorganic pyrophosphate, and T7 RNA poly-
merase, and incubated at 40°C for 2 hours. The amplified
control jugular vein and remodeled vein cRNAs were la-
beled with cyanine 3 and cyanine 5, respectively, and then
purified using an RNeasy mini column (Qiagen). RNA
quality was evaluated using Bioanalyzer 2100 (Agilent
Technologies).
Oligonucleotide microarray hybridization. Agilent
Oligonucleotide Mouse Developmental 22K microarrays
(20,280 genes) were used in these experiments. Two mi-
crograms of labeled cRNA of the jugular vein and remod-
eled vein was fragmented in fragmentation buffer for 30
minutes at 60°C. Hybridization buffer was added to termi-
nate the fragmentation reaction. The labeled cRNA sam-
ples were hybridized to the oligonucleotide Agilent Mouse
Developmental 22K microarray slide for 17 hours at 60°C.
The slide was serially washed with wash solution 1 and 2.
The microarray slides were then scanned using an Agilent
scanner. The images from the three independent experi-
ments were quantified by using Agilent Feature Extraction
software, and the data were then transferred to Argus, a
database designed in our laboratory, to facilitate statistical
analysis.10
Immunohistochemical analysis. Five micrometer sec-
tions of the remodeled vein (starting 1 mm distal to the
microvascular catheter), contralateral control jugular vein,
and sham operated vessels were processed for histology and
immunohistochemistry. Slides were stained with amodified
Movat’s pentachrome for gross morphologic examina-
tion. Specimens were fixed with 10% buffered formalin and
then sequentially stained with Alcian blue, alkaline alcohol,
Verhoeff’s hematoxylin, 2% ferric chloride, sodium thio-
sulfate, crocein scarlet-acid fuchsin, 0.5% acetic acid, 5%
phosphotungstic acid, saffronic alcohol, graded alcohol
dehydration, and then mounted with Permount (Fisher
Scientific).
Frozen sections were fixed with acetone, serially
blocked with normal serum and 1% peroxide, and then
incubated with primary antibody, followed by secondary
antibody conjugated to peroxidase. Slides were then devel-
oped using AEC chromogen and counterstained with Gill’s
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ence of lysyl oxidase (rabbit antirat antibody, 1:250, Dr.
Herbert Kagan, Boston University School of Medicine,
Boston, Mass) and osteopontin (goat antimouse antibody,
1:32, Sigma, St. Louis, Mo). Additional blocking with
avidin and biotin was performed before incubating with
anti-tenascin-C (rat antimouse antibody, 1:6000, Sigma).
Slides were then incubated with secondary biotinylated
antibody and then treated with the ABC Elite peroxidase
kit (Vector Laboratory, Burlingame, Calif) and developed
using AEC chromogen and counterstained.
DAKO Animal Research Kit for Peroxidase (DAKO
Cytomation, Carpinteria, Calif) was used to stain sections
for anti-thrombospondin (mouse monoclonal antibody to
thrombospondin 1 with mild cross-reactivity to throm-
bospondin 2, 1:20, Lab Vision Corporation, Fremont,
Calif). Sections were fixed in acetone, blocked for endoge-
nous peroxidase using 3% peroxide, and then incubated
with biotinylated anti-thrombospondin. Slides were then
treated with streptavidin-peroxidase, developed with an
AEC chromogen, and counterstained. A negative control
was performed by substituting an isotype immunoglobulin
G antibody.
Morphometry. Morphometric analysis was performed
on specimens stained with Movat’s pentachrome. Digital
images were analyzed using ImageJ 1.34.11 Wall thickness
was measured at 8 points (45°) around the vessel circum-
ference from the endothelium to the tissue edge and then
averaged for each sample (n  4 for each time point).12
Statistics. Data from the microarray analysis are com-
pared using Z-pool, an intensity-based variance estimation
algorithm previously developed in our laboratory.13 Differ-
ences were considered to be significant at P  .05. Data
from the morphometric analysis are expressed as mean 
SD. Comparisons were made using a two-tailed Student’s
t test. Differences were considered to be significant at
P  .05.
RESULTS
Transcriptional profiling of venous remodeling.
To begin characterizing the early stages of venous remod-
eling, we performed transcriptional profiling experiments
to compare remodeled veins (7 days after surgery) with
control jugular veins. Of the 20,280 genes represented in
the microarray used in this study, 12,044 and 12,362 genes
were expressed at intensities above threshold in the remod-
eled vein and jugular vein, respectively. There were 131
significantly upregulated and 165 downregulated genes in
the remodeled vein compared with the control jugular vein
(Fig 1). Genes upregulated during venous remodeling,
when classified by biologic function, fell into three main
categories: reorganization of the ECM, chemokine signal-
ing, and platelet-derived growth factor (PDGF) signaling.
Tables I and II list the highly upregulated and downregu-
lated genes, respectively, in the remodeled vein compared
with the control vein. The entire microarray data organized
as a searchable database as well as supplemental methodsand figures can be found at http://vessels.bwh.harvard.
edu/abeles/1.
Changes in the extracellular matrix during venous
remodeling. As several highly regulated genes defined by
the transcriptional profiling experiments have a role in
ECM remodeling, we first performed experiments to define
the gross histologic changes in the extracellular milieu
experienced by the vascular wall during venous remodeling.
To this end, Movat’s pentachrome staining was used to
define all elements of connective tissue: nuclei and elastin
are stained black, collagen is yellow, muscle is red, and
ground substance is blue. When this stain is used, the sham
operated carotid artery displays distinct lamellae of VSMCs
alternating with elastin and a thin rim of collagen in the
adventitia (Fig 2, A). The wall of the control jugular vein is
comprised of one layer of VSMCs, surrounded by collagen
and a small amount of ground substance at the tissue edge
(Fig 2, B). On day 1, ground substance is observed along
with an increase in vessel wall thickness (Fig 2, C). The
wall thickens as the amount of ground substance increases
during days 3 to 5, after which ground substance disappears
(Fig 2, D and E). Additional VSMCs i n t h e subendothelial
layer are also visualized on day 5 (Fig 2, E). By day 7, the
wall consists of collagen and subendothelial VSMCs, and
no ground substance is observed (Fig 2, F). Interestingly, at
the junction of these two layers, elastin is observed as small
black punctuate dots and wisps demonstrating a primitive
internal elastic lamina that appears 7 days after the vein is
first exposed to arterial flow (Fig 2, F inset).
Morphometric analysis was used to obtain total wall
thickness measurements on days 1, 3, 5, and 7, and in
control jugular vein to account for the observed changes
in the ECM. Within 24 hours of surgery, the vein wall
increased in thickness from 72.06  1.68 m to 151.09
 0.84 m. By day 3, wall thickness has reached its
maximum at 220.24  11.87 m. The change in wall
Fig 1. Differential gene expression in remodeled versus con-
trol external jugular veins. Up-regulated genes are visualized as
shades of red, corresponding to P  .05, above the unity line.
Down-regulated genes are visualized as shades of blue below the
unity line.thickness can be attributed to a greater amount of
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as a change in vascular permeability that coincides with
an acute inflammatory response (present in our model by
day 3). Wall thickness has decreased to 191.78  2.20
m by 5 days after surgery and to 157.16 12.83 m by
day 7. The change in wall thickness at each time point
was significant when compared with the control (P 
.001) (Fig 2, G ).
Expression of extracellular matrix proteins during
venous remodeling. The transcriptional profile of the re-
modeled vein revealed significantly upregulated genes in-
volved in the reorganization of the ECM. To confirm these
changes, immunohistochemistry was performed using four
matrix proteins shown to be highly upregulated in the array
experiments (tenascin-C, thrombospondin, lysyl oxidase,
and osteopontin) and that have previously been implicated
Table I. Genes significantly up-regulated in the remodele
Locus link Gene name (symbol)
20750 Osteopontin (Spp1)
14264 Fibromodulin (Fmod)
21923 Tenascin (Tnc)
12837 Procollagen, type VIII (Col8a1)
20296 PDGF-inducible gene (JE protein)
16948 Lysyl oxidase (Lox)
12774 C-C chemokine receptor 5 (Ccr5)
18596 PDGF receptor,  polypeptide (Pdgfrb)
26432 Procollagen lysine hydroxylase* (Plod2)
21826 Thrombospondin 2 (Thbs2)
21825 Thrombospondin 1 (Thbs1)
12831 Procollagen, type V (Col5a1)
54199 C-C receptor 2 (Cmkbr2)
21928 TNF-–induced protein 2 (Tnfaip2)
17387 MMP 14 (Mmp14)
12822 Procollagen, type XVIII (Col18a1)
12111 Biglycan (Bgn)
18590 PDGF- (Pdgfa)
16950 Lysyl oxidase-like 3 (Loxl3)
216725 ADAM-TS 2 precursor (Adamts2)
PDGF, Platelet-derived growth factor; TNF, tumor necrosis factor; MMP
thrombospondin motifs.
*2-oxoglutarate 5-dioxygenase 2.
Table II. Top 10 genes significantly down-regulated in th
Locus link Gene name (symbol)
18534 Phosphoenolpyruvate carboxykinase 1, cytosolic (Pck
170439 Long-chain fatty-acyl elongase (Lce)
17436 Malic enzyme, supernatant (Mod1)
12683 Cell death-inducing DFFA  subunit-like effector A
14555 Glycerol phosphate dehydrogenase 1, cytoplasmic (G
55951 Brain protein 44-like (Brp44l)
12491 CD 36 antigen (Cd36)
11641 A kinase anchor protein 2 (Akap2)
20528 Solute carrier family 2 (facilitated glucose transporter
member 4 (Slc2a4)
14732 Glycerol-3-phosphate acyltransferase, mitochondrial
DFFA, DNA fragmentation factor.in matrix organization.14-17Tenascin-C, an ECM glycoprotein expressed during
remodeling,18,19 is not visualized in the control carotid
artery or the control jugular vein (Fig 3, A and B). By day 1,
tenascin-C is expressed in subendothelial VSMCs (Fig 3, C).
The expression continues to be observed in these cells
and in inflammatory cells within the vessel wall by day 3
(Fig 3, D). By days 5 and 7, tenascin-C expression is seen
throughout the wall of the remodeling vein (Fig 3, E
and F ).
We next examined the expression of thrombospondin,
an adhesion-modulating protein of the ECM.6 Throm-
bospondin is not expressed in the carotid artery or control
jugular vein (Fig 3, G and H). By day 1, expression is
visualized in infiltrating inflammatory cells (Fig 3, I ).
Thrombospondin continues to be observed in these cells by
day 3 (Fig 3, J ). Five days after surgery, expression is
n when compared to the control vein.
Fold change P Biologic function
12.33 106 Extracellular matrix
5.27 1015 Extracellular matrix
4.67 1015 Extracellular matrix
4.32 1015 Extracellular matrix
3.85 1015 PDGF signaling
3.18 1015 Extracellular matrix
3.09 1011 Chemokine signaling
3.03 1015 PDGF signaling
2.95 104 Extracellular matrix
2.90 1015 Extracellular matrix
2.83 1010 Extracellular matrix
2.73 1015 Extracellular matrix
2.44 1015 Chemokine signaling
2.35 108 Chemokine signaling
2.32 1015 Extracellular matrix
2.06 1010 Extracellular matrix
2.03 105 Extracellular matrix
1.98 1012 PDGF signaling
1.76 103 Extracellular matrix
1.72 105 Extracellular matrix
rix metalloproteinase; ADAM, A disintegrin and metalloproteinase with
odeled vein when compared to the control vein.
Fold change P Biologic function
7.43 1015 Carbohydrate metabolism
5.69 1015 Lipid metabolism
5.03 1015 Carbohydrate metabolism
a) 4.38 1015 Apoptosis
4.11 1015 Lipid metabolism
2.68 1015 Apoptosis
2.68 1015 Lipid transport, Signal transduction
2.66 1015 Signal transduction
2.56 1015 Glucose transport
) 2.36 107 Lipid metabolismd vei
, mate rem
1)
(Cide
pd1)
),
(Gpamprominent in the endothelium and VSMCs (Fig 3, K ). By
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Volume 44, Number 4 Abeles et al 867Fig 2. Morphological changes in the vessel wall visualized by Movat’s pentachrome stain. (A) Sham operated
carotid artery. (B) Contralateral control external jugular vein. (C) Remodeled vein on day 1. (D) Remodeled vein on
day 3. (E) Remodeled vein on day 5. (F) Remodeled on day 7. Inset in right lower corner: note the wisps of elastin in
black, magnification: 1000x. The lumen of the vessel, indicated as L, is at the top of all images. Magnification: 400x.
Scale bar: 50 microns. (G) Total wall thickness measured in microns.Fig 3. Immunohistochemistry of the remodeled vein. EJV  external jugular vein. Tn-C  tenascin-c. TSP 
thrombospondin. The arrows in (I) and (J) indicate thrombospondin expression in inflammatory cells. LO  lysyl
oxidase. The arrow in (O) indicates lysyl oxidase expression in inflammatory cells. OPN osteopontin. The arrowhead
and arrow in (U) indicates osteopontin expression in endothelial cells and inflammatory cells respectively. The lumen
of the vessel, indicated as L, is at the top of all images. Magnification: 400x. Scale bar: 50 microns.
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remodeling vein (Fig 3, L ).
Lysyl oxidase, an enzyme that initiates the cross-linking
of collagen and elastin fibers,16 is not expressed in the
control carotid artery or jugular vein (Fig 3, M and N ).
By day 1, it is visualized in infiltrating inflammatory cells
(Fig 3, O). The expression of lysyl oxidase is more promi-
nent in these cells and VSMCs on day 3 (Fig 3, P). Five days
after surgery, lysyl oxidase is observed throughout the
vessel wall (Fig 3, Q). This pattern of expression is also seen
on day 7 (Fig 3, R).
Finally, osteopontin, an adhesion modulating protein
of the ECM that is also implicated in collagen organiza-
tion6,20 is minimally expressed in the carotid artery and
jugular vein (Fig 3, S and T ). By day 1, it is observed
sporadically in the endothelium and in infiltrating inflam-
matory cells (Fig 3, U ). Osteopontin is visualized through-
out the wall in the endothelium, inflammatory cells,
VSMCs, and along the tissue edge 3 days after surgery
(Fig 3, V ). By days 5 and 7, osteopontin is expressed
throughout the vessel wall, including the endothelium and
VSMCs (Fig 3, W and X ).
DISCUSSION
AVFs are widely used for vascular access for hemodial-
ysis. The remodeling of the venous outflow tract depends
on the ability of the vessel wall to adapt to changes in its
biomechanical environment, and this event is critical for
i t s patency.3 Nevertheless, the molecular mechanisms by
which the vein remodels remain unknown. Transcriptional
profiling can provide new insights into venous remodeling.
Kalish et al21 previously used this technology to identify
differentially regulated genes in canine interposition vein
grafts 30 days of surgery. Here, we have used microarray
analysis to identify the transcriptional profile of genes in-
volved in the adaptive response of venous remodeling in
our model. The array employed, although representing a
large number of genes (20,280), was biased toward genes
important in development. By utilizing these arrays, we
were able to elucidate which genes, of those expressed
mainly during murine development, are important for ve-
nous remodeling in an adult.
Three main categories of biologically significant genes
emerged: chemokine signaling, PDGF signaling, and reor-
ganization of the ECM. Chemokine signaling has been
implicated in VSMC migration and proliferation result-
ing in intimal hyperplasia as a consequence of arterial in-
jury.22,23 PDGF signaling has also been implicated in
intimal hyperplasia owing to VSMC migration and prolif-
eration in models of arterial injury and venous remodel-
ing.24,25 Importantly, Kalish et al21 demonstrates an up-
regulation of different collagen types and their precursors
during the first 7 days after vein grafting. These observa-
tions, together with the data presented in this study,
strongly suggest an important role for the ECM during the
early stages of venous remodeling.
Changes in the ECM have been previously described
in other models of vascular remodeling.26,27 These stud-ies have demonstrated that the ECM of a vessel is not a
static entity. It is constantly degraded by various gelatinases
and collagenases that constitute matrix metalloproteinases
(MMPs) and then resynthesized.28 The ECM consists of
collagen, elastin, and a watery, gel-like ground substance.
It has been postulated that the ground substance allows
the ECM to resist compressive forces.6 During venous
remodeling, VSMCs must separate from their ECM to
migrate to the intima and proliferate, creating a neointima.
The activation of MMPs is critical in promoting VSMC
migration.29 The expression of adhesion-modulating gly-
coproteins, such as osteopontin, tenascin-C, and throm-
bospondin, is induced, and their counter-adhesive proper-
ties allow VSMCs to migrate through the vessel wall from
the media to the intima.6,18,30 These glycoproteins have
also been implicated in matrix organization.14,15,17
By using a modified Movat’s pentachrome stain, we
were able to delineate all the components of the remodeled
vein wall, including changes in the ECM in response to
venous remodeling. Furthermore, we demonstrated total
wall thickness increases until it reaches a maximum thick-
ness on day 3. This increase in wall thickness coincides with
an increased amount of ground substance present. Of in-
terest is that this peak of wall thickness and the magnitude
of ground substance also corresponds to the maximum
influx of inflammatory cells noted in our past study.8 A
change in vascular permeability, usually associated with an
acute inflammatory response, may be reflected in the total
wall thickness at early remodeling stages. How the inflam-
matory response leads to the presence of ground substance
and their contribution to venous remodeling remains un-
known.
Elastin is first observed on day 7. It is interesting to see
that the elastin is deposited first as wisps. Elastin fibers in
canine saphenous vein grafts were also noted to be perpen-
dicular to the longitudinal axis of the vessel and did not
form the characteristic lamellae observed in arteries after 3
months’ implantation into the femoral artery.26 Whether
the organization of elastin during venous remodeling will
mature into the alternating lamellae observed in arteries
remains unknown. The deposition of elastin likely confers
strength and integrity to the vessel wall, allowing it to
endure the hemodynamic environment inherent to arterial
flow.
Our studies also documented changes in specific ECM
proteins as suggested by the microarray data. Immuno-
histochemical staining revealed expression of tenascin-C
throughout the entire vessel wall during the early stages of
venous remodeling. Tenascin-C is an adhesion-modulating
glycoprotein of the ECM expressed only in times of inflam-
mation, injury, and tissue remodeling in the adult.14,19 It
has been shown to block the adhesion of VSMCs to fi-
bronectin and promote their migration.31 Tenascin-C
knockout mice have altered matrix organization as a result
of decreased fibronectin deposition in models of wound
healing.32 In addition, tenascin-C is only expressed in
patent coronary vein grafts.33 Our data are in accordance
with previous published studies. Tenascin-C is indeed ex-
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ing and not expressed when a vessel is in its normal envi-
ronment. Its early expression correlates with the migration
of VSMCs to the intima and the organization of the new
ECM during venous remodeling.
Thrombospondin is another adhesion modulating ma-
trix protein that has limited expression in normal vessels.6
In response to balloon injury of the carotid artery, how-
ever, thrombospondin expression leads to increased VSMC
proliferation and acts as a potential chemoattractant for
their migration to the intima.34,35 Mice lacking throm-
bospondin (1, 2 double knockout) have altered wound
healing as evidenced by less dense collagen deposition.15
Our data reveal the expression of thrombospondin is an
important part of the early response to a change in biome-
chanical environment. Its adhesion-modulating properties
likely promote VSMC migration; however, its role in col-
lagen organization during venous remodeling is unknown.
Lysyl oxidase, a copper-dependent monoamine oxi-
dase, is important for structural integrity of the vessel wall.
It initiates the cross-linking of collagen and elastin fibers,
resulting in stiff collagen fibers and elastin fibers that can
stretch and recoil.16,36,37 Although not yet investigated for
its role in venous remodeling, its expression is induced by
arterial balloon injury.38 Lysyl oxidase null mice have dis-
continuous collagen and elastin lamellae leading to dimin-
ished resilience and tensile strength of arterial walls, result-
ing in aneurysms and subsequent death at birth due to
rupture.39,40 Our data indicate that lysyl oxidase is present
during venous remodeling as a new ECM is being synthe-
sized. The expression patterns of lysyl oxidase and elastin
suggest components of the ECM cross-link to confer
strength and stability to remodeled veins as they are sub-
jected to the hemodynamic forces intrinsic to arterial flow.
Osteopontin is an adhesionmodulating glycoprotein of
the ECM that promotes VSMC migration.6 It is interesting
to note that osteopontin null mice have arteries with loosely
organized collagen fibers as well as an increase in vascular
compliance.17 These mice also demonstrated defects in the
organization of collagen in models of wound healing.20
Osteopontin has several roles during the early stages of
venous remodeling. First, as an adhesion modulating pro-
tein, it promotes VSMC migration within the vessel wall.
Second, it likely confers a decreased vascular compliance to
the remodeled vein by promoting organization of collagen
fibers. This in turn allows the vessel to withstand the high
arterial pressures of its new environment. The exact mech-
anism by which osteopontin promotes collagen organiza-
tion remains unknown.
One limitation of this study is that our mouse model of
an AVF examines the early stages of venous remodeling,
focusing on changes that occur in the vessel wall during the
first week after surgery. However, the structural and func-
tional changes that occur during remodeling continue for
weeks to months postoperatively. Continuing to investi-
gate our model at later time points will lead to further
insight into AVF maturation, which may suggest novel
approaches for achieving higher patency rates.CONCLUSION
The early stages of venous remodeling and subse-
quent matrix reorganization occur throughout the entire
vessel wall in our AVF model. Elastin, tenascin-C, throm-
bospondin, lysyl oxidase, and osteopontin are expressed
resulting in the de novo formation of an ECM scaffold that
may be part of a critical adaptive program being evoked to
allow the vessel to cope with its new biomechanical envi-
ronment.
We thank Dr. Herbert Kagan (Boston University
School of Medicine, Boston, Massachusetts) for his kind
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